Table 3.
Combined analysis of groups B and C (univariate and multivariate analysis of factors associated with better survival after RECIST PD)
| Characteristics | Univariate | Multivariate | ||||
| HR | 95% CI | p | HR | 95% CI | p | |
| Gender (men over women) | 1.48 | 1.10 to 2.01 | <0.05 | 2.06 | 1.36 to 3.12 | <0.01 |
| Age (≥70 over others) | 1.30 | 0.98 to 1.74 | .07 | 1.91 | 1.38 to 2.64 | <0.01 |
| EGFR (exon 19 deletion over others) | 0.76 | 0.56 to 1.01 | .06 | 0.71 | 0.52 to 0.97 | .03 |
| Agent (erlotinib over gefitinib) | 0.64 | 0.37 to 1.10 | .10 | 0.54 | 0.30 to 0.95 | .03 |
| Site of metastasis (CNS over others) | 1.32 | 0.97 to 1.79 | .08 | 1.47 | 1.05 to 2.06 | .03 |
| Smoking* at group C | – | – | – | 1.77 | 0.92 to 3.39 | .09 |
| Smoking* at group B | – | – | – | 0.50 | 0.31 to 0.80 | <0.01 |
| PS† at group C | – | – | – | 2.18 | 1.17 to 4.06 | .01 |
| PS† at group B | – | – | – | 4.77 | 3.03 to 7.49 | <0.01 |
*Smoking (current over others).
†PS (2–4 over 0–1).
CNS, central nervous system; EGFR, epidermal growth factor receptor; PD, progressive disease; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.